Affluent Medical

Capital/Financing Update • Jan 12, 2023

PRESS RELEASE

Half-year liquidity contract statement for Affluent Medical

Aix-en-Provence, January 12, 2023 - 17h45 - Under the liquidity contract entered into between Affluent Medical and Kepler Cheuvreux, the following resources appeared on the liquidity account on December 31st , 2022:

• 110,144 shares
• € 22,697.72

During the second half of 2022, were traded a total of:

• on buy side, 32,258 shares for € 82,181.80 (333 executions)
• on sell side, 13,900 shares for € 33,571.60 (208 executions)

As a reminder:

• the following resources appeared on the last half year statement on 30 June 2022 on the liquidity account:
• 91,786 shares
• € 41,304.07
• During the first half of 2022, were traded a total of:
• on buy side, 38,811 shares for € 177,637.19 (359 executions)
• on sell side, 12,062 shares for € 51,976.96 (173 executions)
• the following resources appeared on the liquidity account when the activity started:
• 0 shares
• € 400,000.00

The implementation of this report is carried out in accordance with AMF Decision N°2021-01 of June 22nd , 2021, renewing the implementation of liquidity contracts for shares as an accepted market practice.

Aggregate buy/sell transactions for each trading day Period from 07/01/2022 to 12/31/2022

	BUY SIDE			SELL SIDE
DATE	Number of executions	Number of shares	Traded volume in EUR	Number of executions	Number of shares	Traded volume in EUR
01/07/2022	3	366	1,273.68	1	1	3.58
04/07/2022	-	-	-	2	200	714.00
05/07/2022	4	600	2,082.00	-	-	-
06/07/2022	1	1	3.44	1	1	3.44
07/07/2022	3	401	1,387.46	-	-	-
08/07/2022	2	200	680.00	1	1	3.41
11/07/2022	4	60	201.60	-	-	-
12/07/2022	4	346	1,141.80	1	1	3.30
13/07/2022	1	1	3.30	1	1	3.30
14/07/2022	1	1	3.31	1	1	3.31
15/07/2022	2	196	638.96	1	1	3.30
18/07/2022	4	601	1,905.17	1	1	3.23
19/07/2022	1	5	15.70	-	-	-
20/07/2022	-	-	-	2	100	331.00
21/07/2022	2	2	6.66	1	8	26.72
22/07/2022	2	51	162.18	1	1	3.34
25/07/2022	7	245	774.20	-	-	-
26/07/2022	1	1	3.14	1	1	3.14
27/07/2022	-	-	-	2	100	322.00
28/07/2022	3	101	317.14	3	81	263.25
29/07/2022	4	201	623.10	2	21	68.04
01/08/2022	-	-	-	3	133	429.59
02/08/2022	1	1	3.20	2	23	74.75
03/08/2022	1	1	3.25	1	1	3.25
04/08/2022	5	800	2,504.00	-	-	-
05/08/2022	-	-	-	3	245	786.45
08/08/2022	-	-	-	3	56	178.64
09/08/2022	1	1	3.11	1	1	3.11
10/08/2022	1	1	3.10	4	145	465.45
11/08/2022	4	344	1,062.96	5	400	1,280.00
12/08/2022	1	1	3.10	2	2	6.30
15/08/2022	4	1,018	3,237.24	4	259	833.98
16/08/2022	8	442	1,409.98	1	40	130.00
17/08/2022	3	351	1,091.61	1	1	3.13
18/08/2022	7	701	2,208.15	1	1	3.20
19/08/2022	5	400	1,252.00	-	-	-
22/08/2022	3	101	318.15	1	1	3.16
23/08/2022	5	421	1,313.52	1	1	3.16
24/08/2022	27	3,045	9,013.20	3	240	720.00
25/08/2022	14	1,181	3,531.19	-	-	-
26/08/2022	2	400	1,192.00	1	1	3.10
29/08/2022	7	1,031	2,938.35	2	600	1,812.00
30/08/2022	3	401	1,154.88	1	1	2.91

COMMUNIQUE DE PRESSE

31/08/2022	7	701	1,899.71	7	801	2,403.00
02/09/2022	2	400	1,128.00	-	-	-
05/09/2022	5	550	1,512.50	-	-	-
06/09/2022	-	-	-	1	300	870.00
07/09/2022	-	-	-	4	600	1,806.00
08/09/2022	1	200	562.00	-	-	-
09/09/2022	3	200	578.00	-	-	-
12/09/2022	-	-	-	4	600	1,818.00
13/09/2022	4	425	1,262.25	8	1,200	3,720.00
				-	-	-
14/09/2022	7	639	1,891.44	-	-	-
15/09/2022	2	53	153.70	-	-	-
16/09/2022	7	1,122	3,107.94	1	1	2.80
19/09/2022	-	-	-	1	5	14.00
20/09/2022	4	600	1,530.00
21/09/2022	3	401	974.43	2	201	512.55
22/09/2022	-	-	-	4	200	510.00
23/09/2022	2	200	500.00	-	-	-
26/09/2022	2	200	460.00	-	-	-
27/09/2022	1	1	2.30	1	1	2.30
28/09/2022	2	13	29.12	-	-	-
29/09/2022	3	358	794.76	1	1	2.26
30/09/2022	1	30	66.00	-	-	-
03/10/2022	3	400	844.00	-	-	-
04/10/2022	8	1,002	2,034.06	1	1	2.15
05/10/2022	3	399	786.03	1	1	2.10
06/10/2022	2	400	768.00	5	361	722.00
07/10/2022	1	1	1.90	1	1	1.90
10/10/2022	5	700	1,267.00	1	3	6.00
11/10/2022	2	200	360.00	1	200	380.00
12/10/2022	-	-	-	3	200	360.00
13/10/2022	4	750	1,320.00	-	-	-
14/10/2022	1	1	1.73	3	301	535.78
17/10/2022	1	1	1.75	7	601	1,111.85
18/10/2022	2	14	25.90	6	401	769.92
19/10/2022	1	187	345.95	3	200	390.00
20/10/2022	5	601	1,105.84	3	9	17.46
21/10/2022	8	720	1,353.60	2	63	122.85
24/10/2022	4	201	381.90	2	2	3.90
25/10/2022	2	300	564.00	2	10	19.50
26/10/2022	6	751	1,396.86	1	1	1.94
27/10/2022	3	300	543.00	2	200	372.00
28/10/2022	1	1	1.89	1	1	1.89
31/10/2022	7	735	1,323.00	-	-	-
01/11/2022	2	16	28.16	4	148	266.40
02/11/2022	2	151	268.78	2	54	97.20
03/11/2022	-	-	-	2	367	664.27
04/11/2022	-	-	-	3	42	77.28
07/11/2022	-	-	-	2	191	351.44
08/11/2022	2	300	537.00	1	1	1.86
09/11/2022	1	1	1.78	1	1	1.78
10/11/2022	2	51	90.78	1	14	25.48
11/11/2022	2	150	270.00	-	-	-

COMMUNIQUE DE PRESSE

14/11/2022	2	90	160.20	1	100	182.00
15/11/2022	3	160	288.00	1	1	1.81
16/11/2022	-	-	-	2	160	288.00
17/11/2022	-	-	-	1	5	9.00
18/11/2022	2	151	265.76	1	1	1.76
21/11/2022	-	-	-	1	1	1.78
22/11/2022	1	1	1.76	2	36	64.80
23/11/2022	1	145	258.10	4	685	1,267.25
24/11/2022	3	351	631.80	4	601	1,135.89
25/11/2022	1	150	270.00	1	300	570.00
29/11/2022	2	11	19.80	3	121	222.64
30/11/2022	3	142	255.60	2	125	230.00
01/12/2022	4	303	539.34	-	-	-
02/12/2022	6	751	1,321.76	1	1	1.80
05/12/2022	2	200	348.00	2	380	676.40
06/12/2022	3	201	349.74	2	143	251.68
07/12/2022	2	151	256.70	3	79	139.83
08/12/2022	1	200	332.00	1	259	442.89
09/12/2022	-	-	-	3	335	582.90
12/12/2022	1	200	340.00	2	7	12.39
15/12/2022	3	401	665.66	3	401	677.69
19/12/2022	-	-	-	3	130	218.40
20/12/2022	-	-	-	3	21	35.28
21/12/2022	1	1	1.68	1	1	1.68
22/12/2022	1	50	82.50	-	-	-
23/12/2022	1	1	1.66	1	1	1.66
27/12/2022	1	150	247.50	1	49	82.32
28/12/2022	1	1	1.68	1	1	1.68
30/12/2022	1	1	1.67	1	1	1.67
TOTAL	333	32,258	82,181.80	208	13,900	33,571.60

About Affluent Medical

Affluent Medical is a French player in MedTech, founded by Truffle Capital, with the ambition of becoming a global leader in the treatment of heart and vascular diseases, which are the world's leading cause of mortality, and urinary incontinence which currently affects one in four adults. Affluent Medical develops next-generation, mini-invasive, innovative implants to restore critical physiological functions in these areas. The four major technologies developed by the company are currently in preclinical and clinical studies. KaliosTM is set to be the first medical device to be marketed in Europe.

For more information: www.affluentmedical.com

Contacts :

AFFLUENT MEDICAL Sébastien LADET Chief executive Officer investor@affluentmedical.com

ACTIFIN, Financial press relations Isabelle DRAY +33 (0)1 56 88 11 29 idray@actifin.fr

ACTIFIN, Financial communications Ghislaine GASPARETTO +33 (0)6 21 10 49 24 affluentmedical@actifin.fr

PRIMATICE, Public relations France Thomas ROBOREL de CLIMENS +33 (0) 6 78 12 97 95 thomasdeclimens@primatice.com